for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Five Prime Therapeutics Inc

FPRX.OQ

Latest Trade

5.23USD

Change

-0.21(-3.86%)

Volume

283,099

Today's Range

5.09

 - 

5.45

52 Week Range

4.89

 - 

14.56

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
5.44
Open
5.41
Volume
283,099
3M AVG Volume
7.46
Today's High
5.45
Today's Low
5.09
52 Week High
14.56
52 Week Low
4.89
Shares Out (MIL)
36.78
Market Cap (MIL)
192.37
Forward P/E
-1.38
Dividend (Yield %)
--

Latest Developments

More

Five Prime Therapeutics Announces Management Transition

Five Prime Therapeutics Q2 Loss Per Share $0.99

Five Prime Therapeutics Q1 Loss Per Share $1.02

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Five Prime Therapeutics Inc

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company's product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma. Its preclinical programs include FPA150, FPA154 and FPT155.

Industry

Biotechnology & Drugs

Contact Info

111 Oyster Point Blvd

+1.415.3655600

http://www.fiveprime.com/

Executive Leadership

William R. Ringo

Chairman of the Board, Interim Chief Executive Officer

David V. Smith

Chief Financial Officer, Executive Vice President, Principal Financial Officer

Helen Louise Collins

Executive Vice President, Chief Medical Officer

David White

Principal Accounting Officer, Vice President - Finance

Francis Willard Sarena

Chief Strategy Officer and Secretary

Key Stats

2.10 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-2.440

2017

-5.380

2018

-4.130

2019(E)

-3.794
Price To Earnings (TTM)
--
Price To Sales (TTM)
10.41
Price To Book (MRQ)
0.89
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-49.77
Return on Equity (TTM)
-45.17

Latest News

BRIEF-Five Prime Therapeutics Announces Collaboration With Roche

* FIVE PRIME THERAPEUTICS ANNOUNCES COLLABORATION WITH ROCHE TO DEVELOP COMPANION DIAGNOSTICS FOR TARGETED IMMUNO-ONCOLOGY INVESTIGATIONAL DRUG CANDIDATES

BRIEF-Five Prime Therapeutics Reports Q1 Loss Per Share $0.63

* FIVE PRIME THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Five Prime Therapeutics Appointed Linda Rubinstein As Interim CFO

* FIVE PRIME THERAPEUTICS INC - ON APRIL 13 APPOINTED LINDA RUBINSTEIN AS INTERIM CHIEF FINANCIAL OFFICER - SEC FILING

BRIEF-Five Prime Therapeutics To Close Bladder Cancer Cohort Of Its Phase 1 FPA144-001 Trial

* TO CLOSE BLADDER CANCER COHORT OF PHASE 1 TRIAL EVALUATING BEMARITUZUMAB TREATING PATIENTS WHOSE TUMORS OVEREXPRESS FGFR2B PROTEIN

BRIEF-Personal Genome Diagnostics enteres into a collaboration with Five Prime Therapeutics

* CO INTENDS TO SUBMIT ASSAY FOR REGULATORY APPROVAL, COMMERCIALIZE IN U.S., EUROPE, JAPAN, CHINA, OTHER COUNTRIES

BRIEF-Five Prime Therapeutics Starts Patient Dosing In Phase 1 Trial In Antibody Study

* FIVE PRIME THERAPEUTICS INITIATES PATIENT DOSING IN PHASE 1 TRIAL OF NOVEL FIRST-IN-CLASS B7-H4 ANTIBODY FPA150 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

BRIEF-Five Prime Therapeutics Announces Executive Change

* BELSKY WILL CONTINUE IN HIS CURRENT ROLE UNTIL APRIL 6, 2018 Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Five Prime Reports Q4 Loss Per Share $1.04

* FIVE PRIME ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Five Prime Therapeutics Announces $25 Mln Payment By Bristol-Myers Squibb

* FIVE PRIME THERAPEUTICS ANNOUNCES $25 MILLION PAYMENT BY BRISTOL-MYERS SQUIBB FOR CABIRALIZUMAB DEVELOPMENT MILESTONE

BRIEF-Five Prime Announces Pricing Of Upsized Public Offering Of Common Stock

* FIVE PRIME ANNOUNCES PRICING OF UPSIZED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Five Prime Announces Proposed Public Offering Of Common Stock

* FIVE PRIME ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Five Prime Therapeutics Earns IND Milestone Payment Under Immune Checkpoint Pathways Discovery Collaboration With Bristol-Myers Squibb

* FIVE PRIME THERAPEUTICS EARNS IND MILESTONE PAYMENT UNDER IMMUNE CHECKPOINT PATHWAYS DISCOVERY COLLABORATION WITH BRISTOL-MYERS SQUIBB AND ANNOUNCES THAT BMS HAS EXTENDED THE RESEARCH TERM OF THIS COLLABORATION FOR A SECOND TIME

BRIEF-Five Prime Therapeutics Submits Investigational New Drug Application For FPA150

* FIVE PRIME THERAPEUTICS SUBMITS INVESTIGATIONAL NEW DRUG APPLICATION FOR NOVEL B7-H4 ANTIBODY FPA150

BRIEF-Five Prime Therapeutics And Zai Lab Announce Exclusive License Agreement

* FIVE PRIME THERAPEUTICS AND ZAI LAB ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR FPA144 ANTI-FGFR2B ANTIBODY IN GREATER CHINA AND GLOBAL STRATEGIC DEVELOPMENT COLLABORATION

BRIEF-Bristol-Myers and Five Prime present early-stage data evaluating Cabiralizumab with Opdivo in patients with advanced solid tumors

* Bristol-Myers Squibb and Five Prime present phase 1a/1b data evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in patients with advanced solid tumors

BRIEF-Five Prime posts Q3 loss of $1.54 per share

* Five prime announces third quarter 2017 results and provides business update

BRIEF-Five Prime Therapeutics appoints Aron Knickerbocker as CEO

* Five Prime Therapeutics announces appointment of Aron Knickerbocker as CEO effective January 1, 2018

BRIEF-Five Prime to feature two oral data presentations at ESMO congress

* Five Prime to feature two oral data presentations at ESMO 2017 congress Source text for Eikon: Further company coverage:

BRIEF-Five Prime Therapeutics delivered to Inhibrx written notice of termination of agreement

* Pursuant to terms of agreement, termination of agreement will become effective on december 27, 2017 (not 'december 27, 201')

BRIEF-Five Prime Therapeutics Q2 loss per share $1.58

* Five Prime announces second quarter 2017 results and provides business update

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up